Abivax SA (ABVX) AI Stock Analysis

• Market Cap: €8.73B
• Dividend Yield: N/A
• Average Volume (3M): 99.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: 18.52%
• Country: FR
• Employees: 69
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.10
• Shares Outstanding: 79,072,624
• 10 Day Avg. Volume: 99,142
• 30 Day Avg. Volume: 99,970
• PEG Ratio: 0.13
• Price to Book (P/B): 10.50
• Price to Sales (P/S): 39.49
• P/FCF Ratio: -2.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €130.00
• Price Target Upside: 17.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: €95.00 ▼(-13.79% Downside)
• Action: Reiterated Date: 12/11/25
• Date: Action: Reiterated 12/11/25

Abivax SA's stock score is primarily driven by strong technical indicators, suggesting positive market momentum. However, financial performance and valuation concerns, including high leverage and negative profitability, weigh heavily on the overall score.

Positive Factors

Proprietary platform and diversified clinical pipeline

Owning a proprietary discovery platform and multiple clinical-stage candidates (ABX464 for IBD and HIV applications) provides durable upside through multi-indication development, licensing or partnerships. Platform-driven pipelines enable repeated R&D productivity over years.

Strong cash position supporting runway

A strong cash balance provides multi-month runway to advance clinical programs and reach regulatory or partnership milestones without immediate dilution. For a clinical-stage biotech, liquidity longevity materially reduces binary financing risk and supports strategic options.

Revenue growth with favorable gross margins

Recent top-line growth combined with favorable gross margins indicates the company can scale revenue efficiently and control direct costs. Sustained revenue expansion with healthy gross margins improves long-term funding prospects and attractiveness to partners or acquirers.

Negative Factors

Persistent unprofitability

Ongoing negative EBIT and net losses reflect structural profitability challenges. Persistent unprofitability forces continued capital raises or partner dependence, reducing strategic flexibility and increasing dilution risk for shareholders over the medium term.

Negative operating and free cash flow

Negative operating and free cash flow indicate the core business does not yet generate self-sustaining cash, creating reliance on financing activity. This elevates execution risk if capital markets tighten and can slow program advancement or force unfavorable funding terms.

High leverage and low equity ratio

Elevated leverage raises fixed obligations and reduces financial flexibility, particularly risky for a clinical-stage biotech with binary R&D outcomes. High debt increases refinancing and covenant risk, constraining ability to invest in multiple programs simultaneously.

Abivax SA Business Overview & Revenue Model

Company Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

How the Company Makes Money

Abivax generates revenue primarily through the advancement of its drug candidates into clinical trials, which may lead to future licensing agreements or partnerships with larger pharmaceutical companies. The company may also receive milestone payments from these partnerships as products move through the development process. Additionally, Abivax could potentially earn royalties on sales of any successfully commercialized products resulting from these collaborations. Research and development grants or funding from public institutions may also contribute to its financial resources.

Abivax SA Financial Statement Overview

Summary

Abivax SA shows significant revenue growth but remains unprofitable with negative EBIT and net income. The high debt-to-equity ratio indicates significant leverage, posing risks. Despite a strong cash position, the negative cash flow from operations highlights challenges in generating cash from core activities.

Income Statement

Abivax SA has shown significant revenue growth from 2023 to 2024, but remains unprofitable with negative EBIT and net income. The company's gross profit margin is favorable, indicating effective cost control relative to revenue. However, the negative net profit margin highlights ongoing challenges in achieving profitability.

Balance Sheet

The financial structure of Abivax SA is marked by a relatively high debt-to-equity ratio, indicating significant leverage which could pose risks. The equity ratio is low, reflecting limited shareholder equity relative to total assets. However, the company maintains a strong cash position, supporting liquidity.

Cash Flow

Abivax SA's cash flow from operations is negative, pointing to challenges in generating cash from its core activities. Free cash flow is also negative, but the company has maintained its liquidity through financing activities. The operating cash flow to net income ratio is unfavorable, indicating reliance on external funding.

Breakdown	TTM	Dec 2024	Mar 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.02M	10.79M	4.62M	4.58M	37.00K	14.00K
Gross Profit	6.02M	10.79M	4.49M	4.51M	-119.00K	-52.00K
EBITDA	-185.44M	-167.68M	-133.21M	-53.31M	-42.20M	-37.74M
Net Income	-195.39M	-176.24M	-147.74M	-60.74M	-42.45M	-37.55M
Balance Sheet
Total Assets	119.64M	205.23M	327.06M	73.35M	110.36M	71.30M
Cash, Cash Equivalents and Short-Term Investments	60.95M	144.22M	260.99M	26.95M	60.70M	29.30M
Total Debt	98.71M	97.36M	55.46M	39.16M	53.45M	33.98M
Total Liabilities	167.92M	164.64M	131.05M	71.47M	81.59M	66.63M
Stockholders Equity	-48.28M	40.58M	196.01M	7.19M	25.93M	17.90M
Cash Flow
Free Cash Flow	-137.42M	-154.72M	-97.39M	-69.55M	-47.30M	-30.72M
Operating Cash Flow	-136.96M	-154.07M	-97.13M	-65.58M	-45.66M	-29.82M
Investing Cash Flow	274.00K	15.76M	-8.10M	-3.73M	-1.46M	-575.00K
Financing Cash Flow	-16.14M	28.21M	335.29M	32.21M	82.68M	49.93M

Abivax SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 110.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Positive. The current price of 110.2 is above the 20-day moving average (MA) of 101.60, above the 50-day MA of 104.68, and above the 200-day MA of 67.08, indicating a bullish trend. The MACD of 2.28 indicates Negative momentum. The RSI at 60.11 is Neutral, neither overbought nor oversold. The STOCH value of 84.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABVX.

Abivax SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNFT	58 Neutral	€391.96M	-10.46	-51.06%	―	-45.41%	-273.69%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ABVX	53 Neutral	€8.73B	-39.35	―	―	―	18.52%
DBV	52 Neutral	€968.55M	-3.76	-241.12%	―	―	3.09%
IPH	47 Neutral	€136.09M	-2.63	-271.32%	―	-75.86%	-30.54%
IVA	47 Neutral	€1.11B	-1.49	―	―	-12.84%	-81.94%
VLA	47 Neutral	€796.43M	-7.47	-55.53%	―	13.48%	-1299.09%